Skip to main content
SanofiPartnership

Sanofi Stock: ScionxBio optimizes mRNA candidates

Source: Autobound Signal API · 81 signals tracked for Sanofi · updated

Get Sanofi's live signals in Claude or ChatGPT, or by API

AskWhat changed at Sanofi this week? Use Autobound signals for sanofi.com.

What happened

Sanofi entered into a global collaboration and licensing agreement with ScionxBio to develop extended-exposure variants of selected mRNA candidates.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

On Wednesday, Sanofi entered into a global collaboration and licensing agreement with ScionxBio. The goal is to develop variants of selected mRNA candidates from Sanofi with extended exposure. The agreement thus opens up an additional development approach. It stands alongside new clinical results for Duvakitug and the expansion of insulin production, while quarterly figures are coming up on October 30. The collaboration relies on ScionxBio's TERA platform. ScionxBio will initially take over the optimization of the selected candidates up to and including validation in living organisms. Subsequently, Sanofi is to take over further development, manufacturing, and commercialization. Thus, the division of labor across the individual development phases is established. ScionxBio is responsible for early optimization, Sanofi for the subsequent steps. The agreement affects selected candidates and is not to be understood as a conversion of the entire mRNA portfolio. For investors, the developmental nature of the collaboration is particularly important. The targeted extended exposure describes the goal of the cooperation, not yet a proven clinical advantage. Furthermore, later responsibility for commercialization does not yet mean the approval of a product. Duvakitug is at a different stage of development. On Tuesday, Sanofi and Teva reported results from a Phase 2b extension study...

Keep reading with a free account

The rest of this article, and every signal for Sanofi, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Partnership

What this signalsA new partnership often opens integration and co-selling work.

Takes effect
Oct 21, 2026

Companies

  • ScionxBioPartnerscionxbio.com

The full record

From the Signal API record

Extraction

Confidence
95%
Detected
Oct 25, 2026
signal_type
news
signal_subtype
partners_with

Use this data

Get every partnership signal for Sanofi and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Sanofi this week?”

  2. Send it to your own tools

    The Signal API returns partnership signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/fa404d94-4143-6a70-c4b7-42e253936dc6 returns this record as JSON. POST /v1/companies/enrich returns every signal for sanofi.com.

{
  "signal_id": "fa404d94-4143-6a70-c4b7-42e253936dc6",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-10-25T05:33:34+00:00",
  "company": {
    "name": "Sanofi",
    "domain": "sanofi.com"
  },
  "data": {
    "url": "https://www.ad-hoc-news.de/boerse/news/unternehmensnachrichten/sanofi-aktie-scionxbio-optimiert-mrna-kandidaten/70407976",
    "title": "Sanofi Stock: ScionxBio optimizes mRNA candidates - ad-hoc-news.de",
    "excerpt": "On Wednesday, Sanofi entered into a global collaboration and licensing agreement with ScionxBio. The goal is to develop variants of selected mRNA candidates from Sanofi with extended exposure. The agreement thus opens up an additional development approach. It stands alongside new clinical results for Duvakitug and the expansion of insulin production, while quarterly figures are coming up on October 30. The collaboration relies on ScionxBio's TERA platform. ScionxBio will initially take over the optimization of the selected candidates up to and including validation in living organisms. Subsequently, Sanofi is to take over further development, manufacturing, and commercialization. Thus, the division of labor across the individual development phases is established. ScionxBio is responsible for early optimization, Sanofi for the subsequent steps. The agreement affects selected candidates and is not to be understood as a conversion of the entire mRNA portfolio. For investors, the developmental nature of the collaboration is particularly important. The targeted extended exposure describes the goal of the cooperation, not yet a proven clinical advantage. Furthermore, later responsibility for commercialization does not yet mean the approval of a product. Duvakitug is at a different stage of development. On Tuesday, Sanofi and Teva reported results from a Phase 2b extension study...",
    "summary": "Sanofi entered into a global collaboration and licensing agreement with ScionxBio to develop extended-exposure variants of selected mRNA candidates.",
    "planning": false,
    "image_url": "https://mdb.ad-hoc-news.de/bild/bild-2830819_1920_1080.webp",
    "confidence": 0.95,
    "published_at": "2026-10-25T05:33:34Z",
    "effective_date": "2026-10-21",
    "article_sentence": "On Wednesday, Sanofi entered into a global collaboration and licensing agreement with ScionxBio.",
    "related_company_name": "ScionxBio",
    "related_company_domain": "scionxbio.com"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.